NCT00263640View on ClinicalTrials.gov

Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

April 30, 2009

Study Completion Date

August 31, 2012

Conditions
Respiratory Hypersensitivity
Interventions
BIOLOGICAL

Acaroid

The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.

DRUG

Placebo

Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.

Trial Locations (1)

21465

Allergopharma GmbH & Co. KG, Reinbek

All Listed Sponsors
lead

Allergopharma GmbH & Co. KG

INDUSTRY

NCT00263640 - Safety and Efficacy of House Dust Mite Allergoid in the Treatment of Bronchial Asthma | Biotech Hunter | Biotech Hunter